Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GDC-4198 / Roche
NCT06299124: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors	Active, not recruiting	1	40	RoW	RGT-419B, Active drug	Regor Pharmaceuticals Inc.	Breast Cancer, Advanced Solid Tumor	07/25	07/25
NCT05304962: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer	Recruiting	1	64	US	RGT-419B, RGT-419B in combination with hormonal therapy	Regor Pharmaceuticals Inc.	Breast Cancer	12/25	09/26
RGT-075 / Regor
NCT05297045: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes	Terminated	2	17	US	RGT001-075, Placebo	Regor Pharmaceuticals Inc.	Type 2 Diabetes Mellitus	05/23	05/23
RGT001-075-203, NCT06277934: A Study of RGT001-075 in Adult Patients With Obesity	Active, not recruiting	2	73	US	RGT001-075, Active drug, Placebo, Placebo drug	Regor Pharmaceuticals Inc.	Obesity	06/24	07/24
COMO-1, NCT06867718: Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions	Active, not recruiting	2	236	US	RGT001-075, Placebo Comparator	Regor Pharmaceuticals Inc.	Obesity or Overweight	09/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GDC-4198 / Roche
NCT06299124: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors	Active, not recruiting	1	40	RoW	RGT-419B, Active drug	Regor Pharmaceuticals Inc.	Breast Cancer, Advanced Solid Tumor	07/25	07/25
NCT05304962: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer	Recruiting	1	64	US	RGT-419B, RGT-419B in combination with hormonal therapy	Regor Pharmaceuticals Inc.	Breast Cancer	12/25	09/26
RGT-075 / Regor
NCT05297045: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes	Terminated	2	17	US	RGT001-075, Placebo	Regor Pharmaceuticals Inc.	Type 2 Diabetes Mellitus	05/23	05/23
RGT001-075-203, NCT06277934: A Study of RGT001-075 in Adult Patients With Obesity	Active, not recruiting	2	73	US	RGT001-075, Active drug, Placebo, Placebo drug	Regor Pharmaceuticals Inc.	Obesity	06/24	07/24
COMO-1, NCT06867718: Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions	Active, not recruiting	2	236	US	RGT001-075, Placebo Comparator	Regor Pharmaceuticals Inc.	Obesity or Overweight	09/25	12/25